Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
979 Leser
Artikel bewerten:
(2)

Delisting of Securities of Genesis Growth Tech Acquisition Corp.; Financial Strategies Acquisition Corp.; Kiromic BioPharma, Inc.; Infinity Pharmaceuticals, Inc.; Molekule Group, Inc.; EBET, Inc.; Shift Technologies, Inc.; Ontrak, Inc.; RVL Pharmaceutical

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the securities of Genesis Growth Tech Acquisition Corp. Genesis Growth Tech Acquisition Corp.'s securities were suspended on July 25, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Financial Strategies Acquisition Corp. Financial Strategies Acquisition Corp.'s securities were suspended on August 31, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Kiromic BioPharma, Inc. Kiromic BioPharma, Inc.'s securities were suspended on September 14, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.'s securities were suspended on September 14, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Molekule Group, Inc. Molekule Group, Inc.'s securities were suspended on October 13, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of EBET, Inc. EBET, Inc.'s securities were suspended on October 13, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Shift Technologies, Inc. Shift Technologies, Inc.'s securities were suspended on October 19, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the preferred stock of Ontrak, Inc. Ontrak, Inc.'s securities were suspended on October 20, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of RVL Pharmaceuticals plc. RVL Pharmaceuticals plc's securities were suspended on October 23, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Biocept, Inc. Biocept, Inc.'s securities were suspended on October 25, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Akumin Inc. Akumin Inc.'s securities were suspended on October 26, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Appreciate Holdings, Inc. Appreciate Holdings, Inc.'s securities were suspended on October 27, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Liberty TripAdvisor Holdings, Inc. Liberty TripAdvisor Holdings, Inc.'s securities were suspended on October 30, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Tempo Automation Holdings, Inc. Tempo Automation Holdings, Inc.'s securities were suspended on November 2, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Medicenna Therapeutics Corp. Medicenna Therapeutics Corp.'s securities were suspended on November 2, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of RiceBran Technologies. RiceBran Technologies's securities were suspended on November 8, 2023, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the securities of Acer Therapeutics Inc. Acer Therapeutics Inc.'s securities were suspended on November 9, 2023, and have not traded on Nasdaq since that time.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq's rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.


© 2023 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.